Why Is uniQure Stock Skyrocketing On Tuesday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2024
0mins
Should l Buy QURE?
Source: Benzinga
Breakthrough in Huntington's Disease Treatment: uniQure N.V. has made significant progress with its treatment AMT-130, as the FDA has agreed on an accelerated approval pathway based on data from ongoing clinical studies, potentially allowing for a quicker route to market.
Stock Performance and Future Plans: Following this announcement, QURE shares have surged by 87.8% to $13.70 in premarket trading, while the company prepares for Biologics License Application activities and plans further engagement with the FDA in early 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.180
Low
33.00
Averages
49.88
High
70.00
Current: 15.180
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V. if they purchased shares between September 24 and October 31, 2025.
- Legal Allegations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which resulted in significant investor losses.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, following FDA's negative stance on its drug AMT-130's approval prospects.
- Investor Rights: KSF law firm urges investors wishing to serve as lead plaintiffs to petition the court before the deadline to protect their rights to recover economic losses.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Disclosure: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA no longer viewed the data from its AMT-130 BLA submission favorably, causing the stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting market disappointment in the company's future prospects.
- Clinical Trial Issues: The lawsuit alleges that uniQure misled investors regarding the approval status of its AMT-130 clinical trials, indicating significant deficiencies in the company's disclosure practices that misled investors.
- Investor Action Recommendation: Affected uniQure investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, indicating that the legal risks faced by the company could impact its future financing and market trust.
See More
uniQure Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against uniQure N.V., alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by April 13, 2026, highlighting serious governance concerns.
- FDA Feedback Impact: On November 3, 2025, uniQure announced a significant shift in FDA's stance regarding its AMT-130 gene therapy BLA submission, indicating that prior clinical data may not suffice, which poses regulatory challenges for the company.
- Stock Price Plunge: Following the negative FDA feedback, uniQure's stock price plummeted by $33.40, or 49.34%, closing at $34.29 on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Severe Legal Consequences: The class action lawsuit and stock decline may expose uniQure to substantial liability, further impacting its ability to raise funds and eroding market trust, potentially hindering future R&D initiatives.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Progress Reminder: Hagens Berman updates its investigation into uniQure N.V., reminding investors to submit applications to be Lead Plaintiff by April 13, 2026, related to the securities class action for shares purchased between September 24 and October 31, 2025.
- FDA Allegations: Reports from March 5 and 6, 2026, reveal FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Details of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period, uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially leading to more disclosures that could influence the case's outcome.
See More
Reminder for uniQure N.V. Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status regarding its pivotal study for Huntington's disease and downplayed the likelihood of delays in its Biologics License Application (BLA), resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Accusations: An FDA official labeled uniQure's lead gene therapy AMT-130 as a 'failed therapy' during a media call, alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and implementation of the company's clinical trials.
- Legal Action Progress: uniQure is facing a securities class action lawsuit alleging it failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, which may have led to significant investor losses following a 49% stock drop.
- Critical Deadline: Investors must apply by April 13, 2026, to become Lead Plaintiff in the upcoming litigation, highlighting the significant legal and regulatory challenges the company is currently facing.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V. if they purchased shares between September 24 and October 31, 2025.
- Legal Allegations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which resulted in significant investor losses.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, following FDA's negative stance on its drug AMT-130's approval prospects.
- Investor Rights: KSF law firm urges investors wishing to serve as lead plaintiffs to petition the court before the deadline to protect their rights to recover economic losses.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Disclosure: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA no longer viewed the data from its AMT-130 BLA submission favorably, causing the stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting market disappointment in the company's future prospects.
- Clinical Trial Issues: The lawsuit alleges that uniQure misled investors regarding the approval status of its AMT-130 clinical trials, indicating significant deficiencies in the company's disclosure practices that misled investors.
- Investor Action Recommendation: Affected uniQure investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, indicating that the legal risks faced by the company could impact its future financing and market trust.
See More
uniQure Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against uniQure N.V., alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by April 13, 2026, highlighting serious governance concerns.
- FDA Feedback Impact: On November 3, 2025, uniQure announced a significant shift in FDA's stance regarding its AMT-130 gene therapy BLA submission, indicating that prior clinical data may not suffice, which poses regulatory challenges for the company.
- Stock Price Plunge: Following the negative FDA feedback, uniQure's stock price plummeted by $33.40, or 49.34%, closing at $34.29 on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Severe Legal Consequences: The class action lawsuit and stock decline may expose uniQure to substantial liability, further impacting its ability to raise funds and eroding market trust, potentially hindering future R&D initiatives.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Progress Reminder: Hagens Berman updates its investigation into uniQure N.V., reminding investors to submit applications to be Lead Plaintiff by April 13, 2026, related to the securities class action for shares purchased between September 24 and October 31, 2025.
- FDA Allegations: Reports from March 5 and 6, 2026, reveal FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Details of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period, uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially leading to more disclosures that could influence the case's outcome.
See More
Reminder for uniQure N.V. Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status regarding its pivotal study for Huntington's disease and downplayed the likelihood of delays in its Biologics License Application (BLA), resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Accusations: An FDA official labeled uniQure's lead gene therapy AMT-130 as a 'failed therapy' during a media call, alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and implementation of the company's clinical trials.
- Legal Action Progress: uniQure is facing a securities class action lawsuit alleging it failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, which may have led to significant investor losses following a 49% stock drop.
- Critical Deadline: Investors must apply by April 13, 2026, to become Lead Plaintiff in the upcoming litigation, highlighting the significant legal and regulatory challenges the company is currently facing.
See More
